INSERM UMR1144, Université Paris Cité, 75018, Paris, France.
Service de Physiologie Clinique - Explorations Fonctionnelles, AP-HP, DMU DREAM, Hôpital Lariboisière, Université Paris Cité, 75010, Paris, France.
Sci Rep. 2023 May 22;13(1):8251. doi: 10.1038/s41598-023-35086-8.
Several disabling symptoms potentially related to dysautonomia have been reported in "long-COVID" patients. Unfortunately, these symptoms are often nonspecific, and autonomic nervous system explorations are rarely performed in these patients. This study aimed to evaluate prospectively a cohort of long-COVID patients presenting severe disabling and non-relapsing symptoms of potential dysautonomia and to identify sensitive tests. Autonomic function was assessed by clinical examination, the Schirmer test; sudomotor evaluation, orthostatic blood pressure (BP) variation, 24-h ambulatory BP monitoring for sympathetic evaluation, and heart rate variation during orthostatism, deep breathing and Valsalva maneuvers for parasympathetic evaluation. Test results were considered abnormal if they reached the lower thresholds defined in publications and in our department. We also compared mean values for autonomic function tests between patients and age-matched controls. Sixteen patients (median age 37 years [31-43 years], 15 women) were included in this study and referred 14.5 months (median) [12.0-16.5 months] after initial infection. Nine had at least one positive SARS-CoV-2 RT-PCR or serology result. Symptoms after SARS-CoV-2 infection were severe, fluctuating and disabling with effort intolerance. Six patients (37.5%) had one or several abnormal test results, affecting the parasympathetic cardiac function in five of them (31%). Mean Valsalva score was significantly lower in patients than in controls. In this cohort of severely disabled long-COVID patients, 37.5% of them had at least one abnormal test result showing a possible contribution of dysautonomia to these nonspecific symptoms. Interestingly, mean values of the Valsalva test were significantly lower in patients than in control subjects, suggesting that normal values thresholds might not be appropriate in this population.
一些与自主神经功能紊乱相关的致残症状已在“长新冠”患者中报告。不幸的是,这些症状通常是非特异性的,这些患者很少进行自主神经系统检查。本研究旨在前瞻性评估一组出现严重、持续性、潜在自主神经功能紊乱相关致残症状的长新冠患者,并确定敏感的检查方法。自主神经功能通过临床检查、Schirmer 试验评估,出汗功能评估,直立位血压(BP)变化,24 小时动态血压监测评估交感神经功能,直立、深呼吸和瓦尔萨尔瓦动作时心率变异性评估副交感神经功能。如果测试结果达到文献和我们科室定义的下限阈值,则认为测试结果异常。我们还比较了患者和年龄匹配的对照组之间自主功能测试的平均值。本研究纳入了 16 名患者(中位年龄 37 岁[31-43 岁],15 名女性),发病后中位时间 14.5 个月[12.0-16.5 个月]就诊。9 名患者至少有一次 SARS-CoV-2 RT-PCR 或血清学阳性结果。SARS-CoV-2 感染后的症状严重、波动且致残,伴有运动不耐受。6 名患者(37.5%)至少有一项测试结果异常,其中 5 名患者(31%)存在副交感心脏功能异常。患者的平均瓦尔萨尔瓦评分显著低于对照组。在这组严重残疾的长新冠患者中,37.5%的患者至少有一项异常测试结果,提示自主神经功能紊乱可能导致这些非特异性症状。有趣的是,患者的瓦尔萨尔瓦测试平均值明显低于对照组,提示在该人群中,正常的阈值可能不适用。